checkAd

    Medigene AG  368  0 Kommentare Medigene participates at further conferences in September

    Business news for the stock market

    Martinsried/Munich (pta006/11.09.2018/07:30) - Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at the following upcoming investor and scientific conferences:

    Phacilitate Cell & Gene Therapy Europe
    Date: 11 - 12 September 2018
    Location: London, UK

    Baader Investment Conference
    Date: 24 - 27 September 2018
    Location: Munich, Germany

    Berenberg Bank and Goldman Sachs German Corporate Conference
    Date: 24 - 26 September 2018
    Location: Munich, Germany

    APV Interactive Workshop on ATMP - Bridging big pharma concepts and ATMP
    Date: 27 - 28 September 2018
    Location: Vienna, Austria
    Dr Kai Pinkernell, CMO and CDO of Medigene AG, is invited to hold a presentation on the topic "Development and commercialization aspects of cellular immunotherapies".

    Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

    For more information, please visit http://www.medigene.com

    This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

    Contact Medigene AG
    Julia Hofmann, Dr. Robert Mayer
    Tel.: +49 - 89 - 20 00 33 - 33 01,
    email: investor@medigene.com

    In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

    (end)

    emitter: Medigene AG
    address: Lochhamer Straße 11, 82152 Planegg
    country: Germany
    contact person: Medigene PR/IR
    phone: +49 89 2000 33 3301
    e-mail: investor@medigene.com
    website: www.medigene.de

    ISIN(s): DE000A1X3W00 (share)
    stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate

    [ source: http://www.pressetext.com/news/20180911006 ]



    Diskutieren Sie über die enthaltenen Werte



    Verfasst von Pressetext (Adhoc)
    Medigene AG Medigene participates at further conferences in September Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at the following upcoming investor and scientific conferences: Phacilitate Cell & Gene Therapy Europe Date: 11 - 12 …

    Schreibe Deinen Kommentar

    Disclaimer